FG Cardio Hypertension
Pharmacogenetics of hypertension
Hypertension is an asymptomatic and easily detected disease, but presents serious and lethal complications if not treated in time. Chronic hypertension is the most important modifiable risk factor for the development of both cardiovascular diseases, and cerebrovascular and renal diseases. Despite the latest advances in the pharmacological treatment of hypertension, not all patients with hypertension can achieve the expected blood pressure levels with the medication and many should combine two or more drugs. This lack of effect of pharmacological treatment of hypertension may be in large part due to genetic causes, since the variation of the human genome is one of the most important factors responsible for modulating the individual response to medications.
The genetic profile FG – Cardio Hypertension studies the main metabolizing enzymes and targets involved in the effect and toxicity of the different pharmacological treatments of hypertension. The analysis provides relevant information about the 33 most used drugs, based on the study of 30 genetic polymorphisms described in the scientific literature, present in the enzymes of the cytochrome P450 system: CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP1A2.
• Patients on pharmacological treatment who wish to customize medication based on their genetic profile
• Patients with drug side effects
• Patients in whom pharmacological treatments do not show the expected results
Next Generation Sequencing (NGS)
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
• Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost, according to the needs of each client.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.